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 Cohesin depletion abrogates induction of dynamic erythroid transcriptional 
programmes 
 Cohesin-dependent dynamic gene expression during erythroid differentiation 






Cohesin complex disruption alters gene expression and Cohesin mutations are 
common in myeloid neoplasia, suggesting a critical role in hematopoiesis. Here, we 
explore Cohesin dynamics and regulation of hematopoietic stem cell homeostasis 
and differentiation. Cohesin binding increases at active regulatory elements only 
during erythroid differentiation. Prior binding of the repressive Ets transcription 
factor Etv6 predicts Cohesin binding at these elements and Etv6 interacts with 
Cohesin at chromatin. Depletion of Cohesin severely impairs erythroid 
differentiation, particularly at Etv6-pre-bound loci, but augments self-renewal 
programmes. Together with corroborative findings in acute myeloid leukemia and 
myelodysplastic syndrome patient samples, these data suggest Cohesin-mediated 
alleviation of Etv6 repression is required for dynamic expression at critical erythroid 






Cohesin is an evolutionary conserved multiprotein complex that topologically 
entraps DNA, thereby establishing interactions of more than one DNA fragment1. 
This Cohesin-mediated DNA tethering occurs across multiple genomic layers and 
regulates critical cellular functions. The Cohesin complex is an absolute requirement 
for replication fork stability2, DNA-damage repair via homologous recombination3 
and, critically, for coordinated sister chromatid cohesion to ensure orderly 
chromosomal segregation4. Recently however, a role for Cohesin has been described 
in coordinating contact between non-contiguous regions of the same DNA strand, 
such as in mediating interactions between proximal and distal cis-regulatory 
elements (e.g. promoter-enhancer interactions) and also in insulation of 
topologically-associating domains (TAD)5–7. Structurally, Cohesin forms a distorted 
ring, with SMC1A/B and SMC3 as its arms, while RAD21 reinforces the interaction of 
the two SMC subunits8. The role of STAG2/1 is less well appreciated but these may 
function during the sensing and recruitment of the complex to DNA9. 
 
Alterations of Cohesin function have been described in both inherited 
developmental disorders such as Cornelia de Lange and Roberts syndromes and via 
somatically acquired mutations in malignancy. Mutations in members of the Cohesin 
complex associate with an unusual mixture of cancer types - Bladder Cancer, 
Glioblastoma, Ewing-Sarcoma and Myeloid Neoplasia10–12. Specifically for Myeloid 
Neoplasia, STAG2 mutations occur at a frequency of ~5-10% in Myelodysplastic 
Syndromes (MDS), de-novo and secondary Acute Myeloid Leukemia (AML), while 
mutations in RAD21, SMC1A and SMC3 altogether display a prevalence of another 
5%13–16. In general Cohesin mutations are heterozygous, although STAG2 and SMC1A 
are X chromosome-linked. The mutations are predicted to confer loss or dominant 
negative functions, and usually lead to a decrement of protein levels of Cohesin 
members11,17.  
 
In Cohesin mutated tumors, and specifically in myeloid malignancies with Cohesin 
mutations, there is no evidence to associate Cohesin mutations with aneuploidy or 
abrogation of proper chromosome segregation17–20. This implies that residual 
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Cohesin function in mutated cells is sufficient to coordinate sister chromatid 
cohesion. Furthermore, several groups have demonstrated in different models that 
loss, down-regulation or over-expression of mutated forms of Cohesin genes cause 
alterations in the balance between hematopoietic stem and progenitor cells (HSPC) 
and differentiated cells that are associated with altered gene expression 
programmes and chromatin accessibility17–19,21,22. These observations are therefore 
compatible with the disease-associated/-causative events occurring through 
Cohesin-associated defects at cis-regulatory loops and/or TAD-boundaries. Indirect 
evidence for altered hematopoiesis in Cohesin-perturbed cells also emerges from 
recent investigations of clonal dynamics of MDS, where patients with STAG2 
mutations significantly associated with high-risk disease, increased progression to 
AML and a shorter overall survival23. 
 
In this study we comprehensively address the function of the Cohesin complex 
during normal hematopoiesis and how its abrogation biases differentiation and 
predisposes towards myeloid malignancy. 
 
Materials and methods 
 
Cell Culture Conditions 
HPC-7 cells (kindly provided by Leif Carlsson, Umeå University Sweden) were 
cultured in Iscove's Modified Dulbecco's Medium (IMDM, Gibco) supplemented 
with 10% Fetal Bovine Serum (FBS, Sigma-Aldrich), 100 ng/μl murine recombinant 
Stem Cell Factor (SCF, Peprothech) and 74.8 mM Monothioglycerol (Sigma-Aldrich). 
For all experiments, cells were used after 1-3 weeks of expansion in liquid culture. 
For the erythroid differentiation, SCF was decreased to 20 ng/μl and human 
recombinant Erythropoietin (EPO, Peprotech) was added at 4 U/l. For the myeloid 
differentiation, SCF was decreased to 20 ng/μl and murine recombinant Interleukin-3 




For the antibodies please refer to the specific section in the Supplemental materials 
and methods. With the exception of the GFP experiments (Figure S6D), which were 
performed on a BD Canto II, flow cytometry was performed on a BD Fortessa. Sorting 
of GFP+ cells was performed on a BD FACS Aria II flow cytometer. 
 
Western blotting 
For the preparation of whole cellular extracts and western blot please refer to our 
previous work24. 
 
Chromatin Immunoprecipitation (ChIP), library preparation, sequencing 
Approximately 15x10e6 cells were suspended in PBS and cross-linked for 15 minutes 
at room temperature by the addition of 1% formaldehyde (Sigma-Aldrich), followed 
by quenching with 125 mM glycine for 5 minutes. Cells were washed 2x in cold PBS 
and stored at −80°C. All ChIP preparations were performed with previously frozen 
cell stocks. Cross-linked cells were thawed on ice, suspended in lysis buffer  (50 mM 
Tris-HCl ph 8.0, 1% SDS, 10 mM EDTA, 1 × Complete® protease inhibitor) and 
sonicated on a Diagenode Bioruptor plus® sonicator for 15 cycles and 30 seconds 
with 30 seconds between cycles. Next, lysates were cleared by centrifugation at 
16,000 rcf. for 10 minutes at 4°C, 25 μL/sample were reserved for input, while the 
remaining lysates were diluted 10X in a modified RIPA buffer (10 mM Tris-HCl ph 8.0, 
1% Triton X-100, 0.1% Na-Deoxycholate, 90 mM NaCl, 1 × Complete® protease 
inhibitor) and incubated for 4 hours with antibodies. Chromatin-antibody conjugates 
were afterwards supplemented with 17.5 ul of each Protein A and G Dynabeads® 
(Thermo Fisher Scientific) and further incubated over night. Next, beads were 
washed three times with wash buffer A (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM 
EDTA pH 8.0, 1% Triton X-100, 0.1% SDS) and two times with wash buffer B (20 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 2 mM EDTA pH 8.0, 1% Triton X-100, 0.1% SDS). DNA 
was eluted off the beads by incubation on a Thermo-mixer (Eppendorf) at 30°C for 
15 minutes and 900 rpm in 125 μL elution buffer (1% SDS, 100 mM NaHCO3). Cross-
link reversal and RNA degradation (with 2 ul of 10 mg/ml RNAse A (Thermo Fisher 
Scientific)) were performed simultaneously for 4 hours at 65°C. The DNA was finally 
purified with the QIAquick PCR Purification Kit® from Qiagen. 
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For ChIP-seq experiments, ChIP DNA was used to prepare multiplexed libraries 
following the Illumina TruSeq DNA Sample Preparation v2® protocol and kit. 
Amplified libraries were size-selected for fragments between 250 and 450 bp. using 
a 2% freshly prepared Low-Range-Agarose Gel. Libraries were quantified by qPCR 
using the NEBNext® Library Quant Kit for Illumina (New England Biolabs) as 
recommended by protocol. Finally, library sizes, purity and free adapters were 
quantified on an Agilent 2100 Bioanalyzer® using the Agilent DNA 1000® Kit as per 
the manufacturers instructions. Libraries were sequenced on an Illumina HiSeq 4000 
for 50 base pairs in single read mode. To avoid adapter hopping, free adapters were 
removed (if present) through a second size-selection in gel, while samples were 
stored separated at -20°C and only multiplexed using unique dual indexing pooling 
combinations of up to 6 indexes/lane. 
 
Promoter Capture Hi-C (pCHiC) 
pCHiC was performed in close analogy to Schoenfelder et al25 with several 
differences, as here highlighted: 1. Cross-linking was performed with a final 
concentration of 1% formaldehyde. 2. Nuclei were isolated during the lysis using 15 
ml Dounce homogenizers (10 strokes with the loose grinding pestle, 10 strokes with 
the tight grinding pestle). 3. Library HiC amplification was performed with 6 cycles. 
Final pCHiC were quantified with Qubit® and quality checked on an Agilent 2100 
Bioanalyzer® using the Agilent DNA High Sensitivity® Kit as per the manufacturers 
instructions. Libraries were sequenced on an Illumina HiSeq 4000 (each library in one 
lane). 
 
Detailed methods for Cloning, virus production, transfection and transduction, 
Chromatin fractionation, Rapid immunoprecipitation mass spectrometry of 
endogenous proteins (RIME), Co-Immunoprecipitation, RNAseq, ChIP-Seq, pCHiC, 





All ChipSeq, promoter Capture HiC and RNASeq data have been deposited in the 
GEO database under the accession numbers GSE129478. Raw RIME-MS will be made 




Cohesin dosage at active cis-regulatory elements varies between hematopoietic 
populations during differentiation 
To determine the role of Cohesin in hematopoiesis, we first assessed the dynamic 
expression patterns of Cohesin members in single murine cells during hematopoietic 
differentiation26. Expression of Cohesin members, as exemplified by Rad21 (Figure 
1A, diffusion plot), differed significantly between HSPC and committed stages, with 
increased expression demonstrated upon differentiation. However, this was not 
uniform across lineages; when we further subdivided progenitors into myeloid 
(defined as Spi1high single cells) and erythroid precursors (Klf1high single cells), we 
observed a marked increase of Rad21, Stag2 and Smc3 expression in erythroid 
progenitors only, with no change evident in myeloid cells (Figures 1A, box plot and 
S1A). Of note, the expression of Smc1a and Stag1 did not significantly differ between 
stem and progenitor populations. 
 
To address if this variable expression of Cohesin member transcripts translated into 
differing global dosages of Cohesin complex protein binding at chromatin between 
earlier HSC, erythroid and myeloid precursors during differentiation, we utilized a 
hematopoietic stem and progenitor cell line, HPC727 (hereafter HPC), that 
recapitulates the epigenetic landscape of murine HSC28. We performed chromatin 
immunoprecipitation followed by parallel sequencing (ChIP-Seq) for Cohesin 
proteins Rad21 (hereafter as a proxy for the whole Cohesin complex) and Smc1a, the 
major Cohesin interaction partner Ctcf, RNA Polymerase II (PolII) and chromatin 
marks for promoters and enhancers: H3K4me3, H3K4me1, and H3K27ac. Cohesin-
bound chromatin regions were classified into active and primed enhancers, active 
and inactive promoters and insulator/other regions (as defined in Figure S1B). In 
agreement with previous studies7, approximately 60% of the Cohesin peaks were 
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enriched at insulators, with the remaining 40% bound to active, H3K27ac-associated, 
regulatory elements (Figure S1C). 
 
To determine dynamic changes in Cohesin binding during hematopoietic 
differentiation, we repeated ChIP-Seq analysis for Rad21, Smc1a and Ctcf in cells that 
were induced for 48 hours with EPO (hereafter Erythroid cells) or 72 hours with IL-3 
(Myeloid cells) (Figure 1B). These time points were chosen as cells still demonstrated 
an HPC surface phenotype, however longitudinal flow analysis demonstrated that 
they were transitioning to more differentiated cells (Figure 1C). A discrete, although 
significant decrease in Rad21 binding at insulators and other elements was noted 
between the HPC and Myeloid cells (Figures 1D-F). This decrease was not shared by 
Smc1a binding (Figure S1D-E). Strikingly, during erythroid differentiation a marked 
increase in both Rad21 and Smc1a binding was demonstrated at active cis-
regulatory, but not insulator, elements (Figures 1D-F and S1D-E). Increased Smc1a 
binding was evident, although Smc1a gene expression did not differ between earlier 
hematopoietic stages and erythroid precursors, possibly due to high base line 
protein expression and, thus, high protein availability. Of note, Erythroid cells also 
displayed increased total protein levels of Rad21 and Stag2 compared to HPC and 
Myeloid cells, highlighting the necessity of increased cohesin protein availability in 
these cells (Figure S1F). In contrast to dynamic pattern of the Cohesin complex, Ctcf 
showed uniformly increased binding across all elements in both differentiated cell 
types (Figures S1G-H). 
 
Taken together, these observations imply different and context-specific 
requirements for Cohesin during erythropoiesis and myelopoiesis, with the pattern 
of expression and binding of Cohesin suggesting it as critical for erythroid 
differentiation. 
 
Global dynamic Cohesin binding at active promoters correlates with H3K27 
acetylation, but not gene expression, during erythroid differentiation. 
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We next wished to correlate Cohesin dosage at chromatin with dynamic histone 
modifications by ChIP-Seq, 3-D promoter-enhancer interaction by promoter based 
Capture Hi-C (pCHiC) and alterations in gene expression by RNA-Seq during erythroid 
differentiation (Figure 2A). Although Rad21 binding was almost globally increased 
upon erythroid differentiation, the degree was noted to be highly variable across the 
genome. Based on this observation we divided all active promoters into 4 notional 
erythroid “differentiation” tiers. Tier1 promoters manifested the strongest increase 
of Rad21 dosage, with this dosage gradually decreasing across the remaining tiers, 
such that Tier4 promoters demonstrated no increase (Figures 2B-C).  
 
We next integrated the dynamics of H3K27ac, pCHiC interactions and gene 
expression changes across the 4 tiers. On a global scale, H3K27ac decreased in 
Erythroid cells compared to HPC (Figure 2D). Of note, the degree of H3K27ac 
alteration significantly correlated with the erythroid differentiation tiers and with 
Rad21/Cohesin binding; the most evident reduction of H3K27 acetylation was 
present in Tier4 promoters and the change in the modification was preserved 
greatest in Tier1 promoters (Figure 2D). However, promoter interaction dynamics 
did not mirror this correlation and demonstrated no coordinated difference between 
the tiers (Figure 2E). To compare gene expression changes between the HPC and the 
Erythroid cell states, genes whose differential expression increased after EPO 
stimulation and erythroid differentiation were termed ‘Erythroid’ genes, and those 
whose expression decreased, and were thus higher in HPC, were called ‘Immature’ 
genes (Figure 2F). As expected, Erythroid genes were enriched for erythroid 
differentiation genesets (Figure S2A). However, when we overlapped our Immature 
and Erythroid genes with the 4 graded tiers of Rad21 binding, we found no 
significant correlation between Rad21 binding level and alterations in gene 
expression (Figure 2G).  
 
We next compared dynamic Rad21 and H3K27ac binding, and 3D interaction 
frequencies at the promoters of Erythroid and Immature genes. Although Rad21 
dosage increased equally at both Erythroid and Immature gene groups upon 
differentiation, a relative increase in H3K27ac, and interaction frequency was noted 
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only at Erythroid genes (Figures S2B-C). For example, the Epo-receptor gene (Epor) is 
upregulated following EPO stimulation, where activation is associated with increased 
Rad21 binding, H3K27ac modification and interaction frequency. In contrast, at the 
Etv5 gene, increased Rad21 binding associates with decreased H3K27ac, interaction 
frequency and decreased expression (Figure 2H).  Taken together, these studies 
indicate that binding of Cohesin alone is not sufficient to instruct erythroid 
differentiation but requires additional factors that allow gene transcription. 
 
Etv6 binding precedes Cohesin binding at cis-regulatory elements of genes 
upregulated during erythropoiesis 
 
During hematopoietic differentiation, transcription is coordinated by co-activators 
such as the p300/Crebbp to deposit H3K27ac at promoters and enhancers29. These 
co-activators are classically recruited by specific hematopoietic- and/or lineage-
specific transcription factors30. We hypothesized that the non-uniform pattern of 
Cohesin binding during normal erythropoietic differentiation is influenced at an 
earlier hematopoietic stage by specific transcription factors. To identify proteins that 
might regulate Cohesin binding, we performed pull-down of endogenous Stag2-
containing chromatin complexes, using a technique that enriches for chromatin 
bound interactions31 (Figure 3A). We initially compared mock knockdown (Luc-HPC) 
and Stag2 knockdown (shS2, Figure S4A) HPC to identify Cohesin interacting 
proteins. Only proteins that were present in all Luc-HPC replicates and displayed 
significantly decreased presence upon Stag2 knockdown (Figure 3B) were 
considered as putative interacting proteins. To generate a high confidence dataset of 
Cohesin interacting proteins, we next performed RIME using Rad21 containing 
chromatin complexes and intersected these with the Stag2-interactors. We could 
demonstrate a strong overlap between the interacting proteins and further 
characterized their presumed functions using gene ontology molecular function 
(GO:MF) overrepresentation (Figure 3C). Most cohesin interactors were nucleic acid-
binding proteins and could be assigned into different groups, based on their putative 
function. One of these groups consisted of 5 hematopoietic transcription factors 
(hTF) - Etv6, Erg, Runx1, Tal1 and Stat5 (Figure 3C). We then determined the 
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genome-wide DNA binding patterns of these hTFs in unstimulated HPC cells, 
including their binding at the erythroid differentiation tiers (Figure 3D). Of the 5 
hTFs, only Etv6 displayed globally enhanced co-binding at the Cohesin-associated 
promoters. Strikingly, Etv6 binding was highest at promoters from Tier 1 loci and 
decreased through the remaining tiers, a pattern directly proportional to Cohesin 
binding during erythroid differentiation. Given that Etv6 is predominantly a 
transcriptional repressor that has been previously associated with maintaining HSC 
function and megakaryopoiesis32, we next assessed the dynamic expression patterns 
of Etv6 during differentiation using published scRNASeq data33 (Figure S3). In 
diametric contrast to Cohesin dynamics, Etv6 was most highly expressed in HSPC and 
strongly decreased during erythroid differentiation. Finally, we confirmed the 
interaction between Etv6 and cohesin by performing Co-Immunoprecipitation of 
Rad21 or Stag2 and western blots for Etv6 (Figure 3E). Taken together, we 
functionally link Etv6 with Cohesin and indirectly suggest that a release of 
transcriptional repression by Etv6 may be required for proper erythroid 
differentiation. 
 
Cohesin deficiency severely impairs erythroid differentiation and expands 
myelopoiesis, but only modestly alters HSPC homeostasis. 
 
The differential landscape of Cohesin binding between HPC and erthyroid cell states 
predicts that Cohesin is critical for the dynamic remodeling of transcription during 
erythropoiesis. To test this, we perturbed the function of Cohesin members in HPC 
(Figure 4A) using inducible knockdown of Stag2 (shS2_HPC), Rad21 (shR21_HPC) or 
Smc1a (shS1a_HPC) (Figures S4A-B). No significant differences in the binding of 
Cohesin proteins or Ctcf were detected upon Cohesin subunit knockdown in HPC 
(Figures 4B, S4C). Additionally, RNA-Seq revealed only minor changes in gene 
expression in Cohesin deficient HPC (Figures 4C, S4D). However, these changes 
consistently decreased signatures of differentiation and, for shR21_HPC and 
shS1a_HPC, enriched for stem cell signatures (Figure S4E) in GSEA analyses. 
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In stark contrast, when we determined the role of Cohesin during erythroid 
differentiation, following knockdown, erythroid differentiation was significantly 
impaired after Rad21, Smc1a, and mostly after Stag2 down-regulation (Figure 4D 
and S4F).  This was also demonstrated at the level of global gene expression changes 
using principle component analysis (PCA) of RNA-Seq. Here, a decreased variance in 
shS2_ery cells in the first component, which coincides with erythroid differentiation 
(Table S3), and marked differences in gene expression between Luc_ery and 
shS2_ery cells were demonstrated (Figures 4E-F). GSEA further highlighted an 
increase of stem cell signatures and lost erythroid and general differentiation 
signatures following knockdown of Stag2 (Figure 4G). Of note, Luc_ery genes (genes 
with significantly higher expression in control cells in comparison to Stag2 
knockdown cells following EPO induction) strongly overlapped (196/288 genes, 68%) 
with the genes upregulated during normal erythroid differentiation (Figure 4H). In 
line with previous studies,17–19 IL-3-driven myelopoiesis was significantly expanded in 
Stag2 and Rad21-perturbed cells (Figures S4G-H). 
 
These data demonstrate that the effects of Cohesin member perturbation are 
context dependent, and are in consonance with our description of the increased 
requirement for Cohesin function during erythroid differentiation. They also 
demonstrate that Cohesin appears to be critical for the expression of dynamic genes 
during erythroid differentiation, rather than the continued expression of steady-
state genes required for the maintenance and homeostasis of the self-renewing 
HSPC state.   
 
Impaired erythroid differentiation directly relates to decreased Cohesin binding at 
erythroid-specific genes. 
 
We next tested if the impairment of erythroid differentiation associated with limiting 
concentrations of Cohesin members relates to a failure of dynamic binding of the 
intact Cohesin at the required cis-regulatory elements that we have previously 
defined during normal erythroid differentiation. We performed ChIP-Seq for Rad21 
in control (Luc_ery) and Cohesin perturbed (shS2_ery) cells and compared signal 
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intensities at active enhancers and promoters and specifically across the erythroid 
differentiation tiers described in Figures 2B-C. The global dosage of Rad21 was only 
mildly, albeit significantly, decreased at the active promoters and enhancers 
following knockdown of Stag2 (Figure 5A). However, across the erythroid 
differentiation tiers, impairment of Rad21 binding was most evident at Tier1 with a 
graded decline in differential binding across the remaining tiers (Figure 5B). The 
levels of the H3K27ac modification also positively correlated with this graded 
alteration of Rad21 binding (Figure 5C). Nevertheless, not all Tier1 promoters 
displayed an impaired binding of Rad21 in shS2_ery cells (Figure S5A), which 
prompted us to further define active promoters with significant differential binding 
of Rad21 following Stag2 knockdown. We identified 782 promoters where Rad21 
dosage was significantly impaired in shS2_ery cells (“lost” promoters) and 80 
promoters with a significant increase of Rad21 signal (“gained” promoters) (Figure 
5D). We next integrated Rad21 and H3K27ac ChIPSeq signal intensities with pCHiC 
interactions and differential gene expression at these “lost” and “gained” promoters 
and could demonstrate that loci where Rad21 binding decreased were associated 
with decreased H3K27ac, impaired interactions and a reduction in gene expression 
(Figures 5E-G). Importantly, marked decreases in Cohesin binding were observed at 
crucial erythropoietic master-regulators, including Klf1 and Gata1, thus providing a 
further explanation for the impaired erythropoietic gene expression programme 
(Figure 5F). Moreover, the “lost” promoters were consistently enriched for 
erythropoiesis and differentiation (Figures S5B-C), thus further linking dynamic 
Cohesin binding requirements to Erythroid and general differentiation genes. 
 
These findings suggest that the impaired erythroid differentiation of Stag2-
perturbed HPC following EPO stimulation relates to decreased Cohesin binding at the 
promoters of a critical subset of Erythroid genes. To corroborate this suggestion, we 
demonstrated a significantly positive correlation between Rad21 binding and gene 
expression, H3K27ac and interaction frequency at the corresponding promoters of 
differentially expressed genes (Figures S5D-F). Examples of critical erythroid genes, 
Klf1 and Gata1, whose expression is enriched in Luc-ery control cells are shown in 
Figures 5H and S5G. 
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Taken together, these data demonstrate that limiting concentrations of functional 
Cohesin, as occurs in Cohesin-mutated myeloid malignancies, impair the normal 
binding patterns of the complex at active promoters/enhancers of critical genes 
during erythroid differentiation. This leads to a correlative decrease in H3K27 
acetylation, interaction between promoters and distal cis-regulatory elements and 
reduced gene expression. Notably, the impairment of Cohesin binding is not uniform 
and is marked at critical regulators of erythropoiesis, explaining the impaired 
erythroid differentiation observed in Cohesin-mutated myeloid malignancies. 
 
Stag2 perturbation leads to preferential loss of Cohesin binding at differentiation 
promoters with strong Etv6 pre-binding 
 
As we have demonstrated, the dynamic pattern of Cohesin binding during 
erythropoiesis appears primed by Etv6. We therefore wondered whether Etv6 
binding would also pre-mark those promoters that lose Cohesin following Stag2 
knockdown. 
 
To test this hypothesis, we initially stratified the global alterations in Rad21 binding 
at active promoters following Stag2 knockdown; we identified 4 erythroid 
perturbation tiers (TierA-D), based on the differences of Rad21 binding between 
shS2_ery and Luc_ery (Figure 6A). As anticipated, there was a degree of overlap 
between the differentiation and perturbation tiers (Figure S6A). Of note, we 
observed strong impairment of Rad21 binding at TierA, intermediate dynamics at 
TierB and TierC and a redistribution/sequestration of Rad21 at the TierD promoters 
in the shS2_ery cells (Figure 6A). We could again demonstrate significant correlation 
of Rad21 binding with dynamic H3K27 acetylation and promoter interaction 
frequencies at these tiers (Figures 6A-C). Moreover, promoters from TierD 
significantly overlapped with genes upregulated following Stag2 knockdown 
(shS2_ery genes), while promoters from TierA significantly overlapped with genes 
whose expression was higher in control cells following Stag2 knockdown (Luc_ery 
genes) (Figures 6A,D). 
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We then determined the DNA binding patterns of the 5 previously identified Cohesin 
co-interacting hTFs at the erythroid perturbation tiers (Figure 6E). Again Etv6 binding 
was highest at promoters from tier A loci and decreased through the remaining tiers, 
implying that Etv6 might contribute to altered erythropoiesis following Stag2 
knockdown. Moreover, Etv6 binding was even more significantly enriched at 
differentiation genes that were also impaired after Stag2 knockdown (common 
peaks between perturbation Tier A and erythroid Tier 1), compared to all Tier1 genes 
(Figure 6F). 
 
Upon erythroid differentiation in our HPC system, as in primary cells, we could 
demonstrate a decrease in Etv6 expression, following EPO stimulation (data not 
shown). We therefore wondered if Etv6 protein abundance and binding to 
chromatin might persist following EPO stimulation of shS2 cells. Of note, we noticed 
a modest and relative increase of Etv6 at the protein level when comparing Stag2 
knock down to unstimulated control HPC cells (Figure 6G). However, this did not 
correlate with an increase in Etv6 transcription, as Luc and shS2 HPC cells displayed 
similar Etv6 mRNA levels (Figure S6B). Looking at protein abundance in greater detail 
within individual cellular compartments in unstimulated cells, we could detect an 
increase in Etv6 in the cytoplasm and nucleoplasm, while the chromatin fraction 
remained equally saturated (Figure 6H). In contrast, during erythroid differentiation, 
Etv6 specifically displayed increased chromatin binding in shS2 cells, demonstrating 
that Etv6 remains active at chromatin following Cohesin loss (Figure 6I). Finally, we 
investigated the Etv6 binding dynamics by ChIP-qPCR at specifically impaired gene 
promoters. We chose the promoter regions of Klf1, Epor and Cxcr4, as these were 
common among the Tier1 and TierA loci and significantly lost Rad21 binding during 
Stag2-perturbed erythroid differentiation. No difference in Etv6 binding was 
observed between Luc_HPC and shS2_HPC cells (Figure 6J). By contrast, Etv6 binding 
significantly decreased during normal erythroid differentiation, however, in 
agreement with its higher availability in shS2_Ery cells, Etv6 binding intensity 
remained significantly higher in shS2_Ery cells compared to Luc_Ery cells (Figure 6J). 
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These data suggest that Cohesin evicts Etv6 from chromatin, relieving its repressive 
function, and that deficiency allows for the continued chromatin binding and 
repressive activity of Etv6 at genes critical for erythroid differentiation. To test this 
hypothesis, we sought to determine if we could rescue erythroid differentiation in 
Cohesin perturbed HPC by concomitantly knocking down Etv6. However, Etv6 is a 
critical regulator of hematopoiesis and its loss leads to impairment of HSC function 
and blood development32. In keeping with this critical function, both single 
knockdown of Etv6 (Luc-shEtv6-HPC) and double knockdown of Stag2 and Etv6 
(shS2-shEtv6-HPC) led to a marked reduction in cellular proliferation, preventing us 
from testing this hypothesis (Figure S6C-D).  
 
Erythropoiesis is impaired in human Cohesin-mutated MDS and AML 
 
Cohesin mutations are common events in myeloid neoplasia. Among Cohesin genes, 
mutations of STAG2 are most frequent13,15,34. To determine if our model of impaired 
erythropoiesis correlates with human disease, we analyzed differential gene 
expression and matched mutational analysis in a dataset consisting of CD34+ bone 
marrow cells from 159 MDS patient samples and 17 healthy donors35. We initially 
analyzed all significant differential transcripts that occurred between 8 STAG2-
mutated and 151 other MDS samples, noting a total count of 2778 genes that were 
differentially expressed (q < 0.05). Consistent with our Cohesin knockdown datasets, 
the Hemoglobin genes and the essential erythroid regulator KLF1 were some of the 
most highly down regulated genes in STAG2 mutated samples (Figure 7A). GSEA 
further highlighted that stem cell signatures were up regulated and erythroid and 
general differentiation signatures down regulated in STAG2-mutated samples (Figure 
7B), in consonance with our murine cellular model of altered Cohesin function. 
Indeed, the majority of the human orthologues of the genes differentially expressed 
during erythroid commitment following Stag2 knock down also showed decreased 
gene expression in STAG2-mutated MDS samples (Figure S7A), further corroborating 
the relevance of our model to human disease. Extending our analysis to Cohesin-
mutated AML, we repeated this analysis in the TCGA LAML dataset36, comparing 
expression changes from 18 Cohesin-mutated patient samples with 133 AML 
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samples from patients who lacked a Cohesin-mutation. Again, there was a marked 
overlap between the genes downregulated in Cohesin-mutated AML and our 
experimental dataset (Figure S7B). 
 
Mutual exclusivity of ETV6 and Cohesin mutations in myeloid malignancies 
supports their functional interaction 
 
ETV6 and Cohesin members are commonly mutated in MDS and AML. To further 
interrogate the functional interaction between ETV6 and Cohesin, we examined the 
pattern of mutations in individual patients from large cohorts of patients with 
myeloid malignancies. Analyzing mutations in a total of 3612 patient samples with 
myeloid malignancies from the Cosmic database37 in which all STAG2 and ETV6 
coding regions were sequenced, we observed that only 4 out of 338 samples 
displayed mutations in both ETV6 and STAG2, suggesting a strong degree of  
tendency towards mutual exclusivity of mutations in these genes ( p<0.001, Figure 
7C). However, perhaps related to the small number of ETV6 mutations, the 
heterogeneity of the myeloid diseases or the lack of full Cohesin member coverage, 
we were relatively underpowered to demonstrate this statistically and mutual 
exclusivity was not significant by Fisher’s exact test (p = 0.4). 
 
To further validate these results and underscore the significance of our mechanistic 
model, we examined cumulative results from an unpublished cohort of 2434 AML 
samples from the UK NCRI AML trials (MRC), 200 AML samples from the TCGA 
consortium36 and 622 AML samples from the Oregon Health & Science University 
(OHSU)38, in which all Cohesin members and ETV6 genes were analyzed for 
mutations. Among a total of 386 472 samples, only one was co-mutated for a 
Cohesin member and ETV6, a comparable frequency to the degree of mutual 
exclusivity between individual members of Cohesin (p<0.001, p=0.028, Figure 7D). Of 
note, full mutual exclusivity between ETV6 (22 samples) and cohesin members 
STAG2/RAD21 was also evident in another large AML dataset (Papaemmanuil et 
al16). These results almost complete mutual exclusivity further corroborate our 
experimental data and strongly support a functional interaction between ETV6 and 
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Cohesin, such that in the absence of physiological levels of Cohesin, intact ETV6 




Multiple studies17–19,21 and the high incidence of mutations of Cohesin members in 
myeloid malignancies13,15,16 have demonstrated that reduced Cohesin dosage 
perturbs hematopoiesis. However, the mechanisms whereby Cohesin maintains 
hematopoietic homeostasis remain obscure. We now present a model that 
highlights the requirement for Cohesin during the dynamic induction of erythroid 
differentiation. We link this requirement to the acetylation of proximal and distal cis-
regulatory elements, to increased interaction between these and to the expression 
of important differentiation genes. Critically, these changes are not uniform across 
the genome but appear coordinated by the prior binding of specific, interacting hTFs, 
such as Etv6. Moreover, we demonstrate the abrogation of dynamic induction of 
these differentiation processes and genes when Cohesin members are depleted. 
Finally, we provide evidence of a functional interaction between ETV6 and Cohesin 
and corroborate its relevance for human disease, correlating our experimental 
findings with large datasets from patients with MDS and AML.  
 
Our model system was chosen to allow temporal and lineage control over 
differentiation and, with it, the interrogation of specific cellular states rather than 
heterogeneous populations of cells along a differentiation continuum. To overcome 
the limitations of a purely in-vitro system, we corroborated our findings at all times 
to more physiological systems, all the way from the expression of the Cohesin 
members in murine and human stem and progenitor cells undergoing 
differentiation, through similarities of our altered gene expression patterns to 
murine self-renewal signatures, all the way to the physiological correlation of our 
data with the genotype-specific disease mutational and gene expression signatures 
in MDS and AML databases. Similarities are seen with phenotypes previously 
described in murine and human hematopoietic cells following Cohesin depletion or 
ever expression of mutated forms 17–19,22, where  decreased erythroid differentiation 
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of human or murine haematopoietic stem and progenitor cells have been 
demonstrated in vitro17, and decreased bone marrow MEP and Ter119+ cells in 
vivo18, although this same study actually showed an increase of extramedullary 
erythroid cells in the spleen. Moreover, our identification of the hTF that interact 
with Cohesin on chromatin may also explain, at least in part, the alterations in 
chromatin accessibility demonstrated upon Cohesin depletion in these studies. Of 
note, increased accessibility at chromatin regions enriched for Erg, Gata2, Runx1 and 
Stat5 binding sites were documented, demonstrating an almost complete overlap 
with the hTF that we detected to interact with Cohesin at chromatin. 
 
We find that Cohesin member perturbation has little direct influence on the 
maintenance of existing transcriptional programmes necessary for HSPC 
homeostasis. This reconciles with previous studies in which only the rapid and 
complete removal of Cohesin from chromatin affects the 3D maintenance of 
chromatin39 and would also explain why malignant cells can tolerate partial loss of 
Cohesin whilst still maintaining proliferation. Our findings of the requirement for 
Cohesin function to induce gene expression during the dynamic process of 
differentiation are in line with a recent study40, where so-called inducible enhancers 
were dependent on Cohesin binding to activate gene expression from their target 
promoters during the dynamic process of macrophage activation following 
inflammatory signaling. However, our data expands on this observation, 
mechanistically highlighting that the induction of dynamic processes, such as 
differentiation, by Cohesin-mediated gene expression programmes is neither 
random nor uniform, but highly specific and appears regulated by pre-bound hTFs. 
We speculate that, within HSPCs, critical erythroid genes are repressed by Etv6. 
However, during normal erythroid differentiation, Cohesin is recruited to these 
critical promoters. This coincides with the loss of Etv6 binding, deposition of the 
activating H3K27ac, increased contact between these promoters and distal cis-
regulatory enhancers and expression of critical erythroid genes. Moreover, during 
normal differentiation Etv6 is downregulated at the transcriptional level to further 
augment this switch. However, under Cohesin insufficiency, e.g. in Cohesin-mutated 
myeloid neoplasia, there is no increase in Cohesin binding and Etv6 remains bound 
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at chromatin, resulting in continued repression of critical erythroid genes and a 
failure to differentiate properly. Moreover, this model is entirely consistent with the 
erythroid differentiation defect evident within patients with Cohesin-mutated 
myeloid neoplasia and is supported by the near mutual exclusivity of ETV6 and 
Cohesin member mutations in myeloid malignancies. 
 
In summary, our data shed considerable light on the function of Cohesin during 
cellular processes that require dynamic gene regulation, such as erythroid 
differentiation. Further investigation is warranted to demonstrate whether Cohesin 
is required for other dynamic cellular processes. We propose a mechanism for 
Cohesin co-ordinated alterations in critical gene expression programmes that relates 
to interaction with specific hTFs such as Etv6. We speculate that other tissue-specific 
TF may regulate Cohesin function in other systems and suggest further studies are 
warranted to test this hypothesis. Finally, we demonstrate that abrogation of 
Cohesin function alters differentiation through the failure to affect a switch from 
repression to activation at specific genes and propose these genes and continued 
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Figure 1. Cohesin dosage at active cis-regulatory elements varies between 
hematopoietic populations during differentiation 
 
A. Left panel - Diffusion map of scRNASeq expression of Rad21, colored in red with 
http://blood.stemcells.cam.ac.uk/geneMap.html. The color corresponds to a log2 
scale of expression ranging between 0 and the maximum value. LT-HSC, HSPC and 
Progenitors are highlighted in approximation of the original single cell sorting. 
Right panel - box plots with 10-90 percentiles of Rad21 expression in the indicated 
populations. Erythroid and Myeloid progenitors were empirically considered as all 
the cells with normalized expression of Klf1 > 10 and Spi1 > 10, respectively. 
B. Graphical schema of the experimental design to determine cohesin dynamics 
during normal erythroid and myeloid differentiation. 
C. Representative longitudinal Flow Cytometry plots. HPCs were differentiated 
towards the erythroid and myeloid lineages. Day 2 of EPO induction was highlighted 
as the optimal Erythroid (or Ery) transition state, while cells induced for 3 days with 
IL-3 were called Myeloid (or Myelo) transition cells. 
D. and E. Density heat map (D) and average profiles (E) of Rad21 binding at Cohesin-
associated regions in the indicated cellular states. 
F. Total count of significant differentially bound Rad21 peaks comparing HPC to the 
indicated differentiation lineage. Left panels show pie charts of genomic location of 
differential bound peaks. Scatter plots (right) - differential Rad21 binding at active 
promoters/enhancers in the indicated populations. Blue dots (Lost) show peaks that 
decrease, while red/purple dots (Gained for Erythroid and Myeloid cells respectively) 
show peaks that increase during differentiation. 
 
Figure 2. Global dynamic Cohesin binding at active promoters correlates with 
H3K27 acetylation, but not gene expression, during erythroid differentiation. 
 
A. Experimental system to determine the role of Cohesin during normal erythroid 
differentiation. 
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B. Left panel - average profile for Rad21 binding at active promoters in the HPC 
(blue) and Erythroid (red) cellular states. Right panel - Representation of the 
erythroid differentiation tiers; density heat maps of Rad21 binding sites from a 
representative experiment (of 2) at active promoters that were split into 4 equal 
tiers, based on the incremental change of Rad21 binding during erythroid 
differentiation. 
C. Box plots and 10-90 percentiles of the differences of Rad21 binding in Erythroid 
cells and HPC (Rad21_Ery minus Rad21_HPC) in the indicated erythroid 
differentiation tiers. Shown are means from 2 replicates. Box plots to the left of zero 
indicate increased binding in HPC and to the right indicate increased binding in 
erythroid differentiating cells. 
D. Box plots and 10-90 percentiles of the differences of H3K27ac binding for the 
same regions as in Fig2C. Shown are means from 2 replicates. 
E. Box plots and 10-90 percentiles of the differences of significant interaction 
frequencies of the baits located at the promoters of the same regions as in Fig2C. 
Interactions were determined with the CHICAGO pipeline. The threshold for 
significance was set at 5. Shown are results from 2 replicates. 
F. Volcano plot showing gene expression changes during HPC to erythroid 
differentiation (3 biological replicates, Luc1, Luc2 and Luc3, were used per group for 
consistency with later experiments). The blue shaded area consists of genes enriched 
in HPC (immature genes), while the red shaded area shows genes whose expression 
significantly increased in the Erythroid cell state (erythroid genes). 
G. Venn diagrams of overlaps between annotated promoters from the erythroid 
differentiation tiers (centre circle) and differentially expressed genes from Fig2F 
(outer circles). Chi-Square analysis was performed for the trend of overlapping 
events across all tiers. 
H. Examples of Rad21 and H3K27ac binding dynamics (upper), as well as interaction 
frequencies (lower arcs) between HPC and Erythroid cellular states for a 
representative erythroid gene (Epor) and an immature gene (Etv5). 
 
Figure 3. Etv6 binding precedes Cohesin binding at cis-regulatory elements of genes 
upregulated during erythropoiesis 
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A. Schematic of methodology to identify Cohesin complex interacting proteins at 
chromatin. 
B. Volcano plot showing differences in pull-down of Stag2 between Luc1_HPC (4 
experimental replicates) and shS2_1_HPC (4 experimental replicates). The brown 
colored dots show significantly associated proteins (padj <0.1, log2FC 0.33). 
C. Upper panel - Venn diagram displaying validation of significant Stag2-associated 
proteins from Figure 3B after RIME pull down with Rad21 (4 technical replicates, 
Luc1_HPC). Lower panel right - Putative Cohesin-interacting proteins that bind 
together at chromatin; Lower panel left - top 5 enrichments of gene ontology (GO) 
molecular functions of the final full list of cohesin interactors (scale is -
log10(qvalue)). 
D. Average profiles demonstrating the enrichment of the specified pre-bound hTF at 
the erythroid differentiation tiers in unstimulated HPC. 
E. Co-immunoprecipitation experiments confirm interaction of Etv6 with Stag2 and 
Rad21. 
 
Figure 4. Cohesin deficiency severely impairs erythroid differentiation but only 
modestly alters HSPC homeostasis 
 
A. Experimental design to determine Cohesin dynamics following perturbation of 
Stag2. 
B. Average profiles of Rad21 binding at active promoters and active enhancers in 
Luc_HPC and shS2_HPC cells. To minimize global quantitative biases, the Rad21 
signal was CPM normalized and internally calibrated to its signal at the 
insulator/other sites (see Methods). Shown are means of 2 replicates, while each 
shRNA was considered an independent replicate (Luc1_HPC, Luc2_HPC, shS2_1 HPC, 
shS2_2_HPC). 
C. Differential gene expression between Luc_HPC and shS2_HPC cells (3 biological 
replicates representing different knock-down clones per group: Luc1_HPC, 
Luc2_HPC, Luc3_HPC, shS2_1_HPC, shS2_2_HPC, shS2_3_HPC) demonstrates 
minimal gene expression changes. The blue shaded area consists of genes enriched 
in HPC, while the brown shaded area shows genes significantly expressed in 
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shS2_HPC cells. The numbers at the upper corners show the counts of log2FC >0.5, 
padj <0.1  and (log2FC >1, padj <0.05) significant differential genes. For comparison, 
the significance and difference spreads were set intentionally to match those in 
Figure 4F. 
D. Representative flow cytometric analysis of erythroid differentiation following EPO 
for Luc_Ery and shS2_Ery at the indicated times. 
E. Variance by PCA analysis of the shCohesin_HPC, Luc_HPC, shS2_ery and Luc_ery 
RNASeq datasets. Each dot represents a different shRNA (Luc1-3_HPC, shS2_1-
3_HPC, shR21_1-3_HPC, shSmc1a_1-2_HPC, Luc1-2_ery, shS2_1-2_ery). 
F. Differential gene expression between Luc_ery and shS2_ery cells (2 biological 
replicates for each group - Luc1_ery, Luc2_ery, shS2_1_ery, shS2_2_ery). The 
numbers at the upper corners show the counts of log2FC >0.5, padj <0.1 and (log2FC 
>1, padj <0.05) significantly differentially expressed genes. 
G. NES for significant (FDR > 0.05 datasets) hematopoiesis-related datasets as 
determined by GSEA. Input was a ranked list of all pajd < 0.1 genes from figure 4F. 
H. Venn diagrams of gene expression changes displaying overlaps between Erythroid 
or Immature genes from Fig. 2F and Luc_ery or shS2_ery genes from Fig. 4F. 
 
Figure 5. Impaired erythroid differentiation directly relates to decreased Cohesin 
complex binding at erythroid-specific genes 
 
A. Rad21 binding at active promoters or active enhancers in Luc_ery (red) and 
shS2_ery cells (black). To minimize global quantitative biases, the Rad21 signal was 
CPM normalized and internally calibrated to its signal at the insulator/other sites. 
Shown are means of 2 replicates (Luc1_ery, Luc2_ery, shS2_1_ery, shS2_2_ery). 
B. Differential Rad21 binding in Luc_ery and shS2_ery cells at the indicated erythroid 
differentiation tiers from Fig. 2B. Box plots to the left of zero indicate increased 
binding following Stag2 knockdown and to the right indicate increased binding in 
control knockdown cells that follow normal erythroid differentiation. Shown are 
means of 2 replicates as described in Figure 5A. 
C. Differential H3K27ac binding as Fig. 2B. Shown are means of 2 replicates as 
described in Figure 5A. 
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D. Differential Rad21 binding at active promoters between Luc_ery (red) and 
shS2_ery cells (blue). Shown are means of 2 replicates as described in Figure 5A. 
E. H3K27ac binding at the sites from Fig5D. Shown are means of 2 replicates as 
described in Figure 5A. 
F. Gene expression differences between Luc_ery and shS2-ery cellular states at the 
indicated sites from Fig5D. Genes that were enriched in Luc_ery were marked with 
negative values (shades of red), while genes that were enriched in shS2_ery were 
marked with positive values (shades of blue). N.e. = not expressed. Selected genes of 
interest are noted. 
G. Interaction frequencies at the indicated sites from Fig5D (at gained promoters - 
blue; at lost promoters - red) are shown as the difference of normalized significant 
interactions between shS2-Ery and Luc-Ery conditions. Shown are means of 2 
replicates as described in Figure 5A. 
H. Example of Rad21 and H3K27ac binding dynamics, as well as interaction 
frequency between Luc_ery and shS2_ery at the Klf1 promoter (RNASeq 
log2foldChange -1.8). 
 
Figure 6. Stag2 perturbation leads to preferential loss of Cohesin binding at 
differentiation promoters with strong Etv6 pre-binding 
 
A. Representation of the erythroid perturbation tiers; differences of Rad21 binding in 
Luc-Ery and shS2-Ery cells (Rad21-Ery minus shS2-Ery) in the indicated erythroid 
perturbation tiers. Box plots to the left of zero indicate increased binding following 
Stag2 knockdown and to the right indicate increased binding in control knockdown 
cells with normal erythroid differentiation. 
B. Differential H3K27ac binding as in Fig6A. 
C. Differential significant interaction frequencies at the promoters of the same 
regions as in Fig6A. 
D. Overlaps between annotated promoters from the indicated perturbation tiers and 
differentially expressed genes from Fig4F. 
E. Enrichment of the specified hTF at the perturbation tiers in wild-type HPC. 
F.  Enrichment of Etv6 at the indicated regions. 
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G. Immunoblotting for total protein expression of Etv6, Stag2 and Actin in the 
indicated conditions. 
H. Immunoblotting for protein expression of Etv6, Stag2 H3 and Actin in different 
cellular fractions in the indicated conditions. 
I. Immunoblotting for protein expression of Etv6, Stag2 H2AX and Actin in different 
cellular fractions in the indicated conditions. 
J. ChIP-qPCR of Etv6 binding at Klf1, Epor and Cxcr4 promoter regions in the 
indicated cellular states. Shown are results from 3 experimental replicates. 
 
Figure 7. Erythropoiesis is impaired in human Cohesin-mutated Myelodysplastic 
Syndromes and Acute Myeloid Leukemia 
 
A. Differential gene expression in STAG2 mutated MDS vs all other MDS subtypes. 
Only events with FDRq<0.1 are shown. The red (enriched in other MDS) and black 
(enriched in shSTAG2mut MDS) segments specify for log2FC >0.5 differential genes. 
Genes of interest are shown. 
B. NES for significant hematopoiesis-related datasets (FDR <0.05) as determined by 
GSEA. Input was a ranked list of all genes from figure 7A. STAG2 mutant-enriched 
genesets are to the right of 0 and other MDS subtype genesets to the left. 
C. and D. Common and exclusive mutations of the indicated genes among 3612 
myeloid neoplasia curated by the Cosmic database (C) and 2434 3256 AML samples 
from the UK NCRI AML trials (2434 samples), BEAT-AML (622) and TCGA LAML (200) 
datasets (D).  
 
 







